Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2001, for Humana Inc., a major health benefits company. As of the reporting date, Humana served approximately 6.5 million members in its medical insurance programs and 2.2 million members in specialty products. The company recently realigned its management structure into two primary segments: Commercial (fully insured, ASO, specialty) and Government (Medicare+Choice, Medicaid, TRICARE). A significant recent transaction was the acquisition of an Anthem Health Insurance subsidiary on May 31, 2001, for approximately $47 million, adding 1.2 million TRICARE members.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2001 | Six Months Ended June 30, 2001 |
|---|---|---|
| Total Revenues | $2,479 | $4,924 |
| Net Income | $25 | $52 |
| Earnings Per Share (Diluted) | $0.15 | $0.31 |
| Medical Expense Ratio | 83.7% | 83.4% |
| SG&A Expense Ratio | 14.2% | 14.3% |
| Cash and Cash Equivalents | $603 | $603 (Ending Balance) |
| Total Debt (Current) | $580 | $580 (Current Portion) |
| Operating Cash Flow | N/A | $(27) Used |
Liquidity: The company maintains a $1.0 billion unsecured revolving credit facility with $520 million outstanding. It also holds $60 million in commercial paper. Statutory capital and surplus for regulated subsidiaries totaled approximately $940 million, exceeding minimum requirements of $604 million.
Material Changes vs. Prior Period
- Revenue Decline: Premium revenues decreased 8.2% to $2.45 billion for the quarter and 7.9% to $4.86 billion for the six-month period compared to 2000. This was driven by strategic exits from non-core markets and products, partially offset by higher premium yields.
- Profitability Improvement: Despite lower revenues, Net Income increased 31.6% ($25M vs $19M) for the quarter and 30% ($52M vs $40M) for the six-month period. This was achieved through improved pricing discipline, benefit reductions in Medicare+Choice, and the elimination of non-core businesses.
- Medical Expense Ratio: Improved significantly to 83.7% (quarter) and 83.4% (six months) from 85.0% in the prior year periods, primarily due to exiting high-cost markets and benefit design changes.
- Membership Shifts: Commercial medical membership declined 18.3% year-over-year, while Government segment membership grew 59.0%, largely due to the new TRICARE acquisition.
- Cash Flow: Net cash used in operating activities was $27 million for the six months ended June 30, 2001, compared to $18 million used in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook: Management continues to focus on exiting non-core businesses and improving infrastructure. Capital expenditures for 2001 are expected to be approximately $130 million, primarily for technology initiatives. The company recently issued $300 million in senior notes (August 2001) to repay credit facility borrowings.
Accounting Changes: The company noted the issuance of FASB Statements No. 141 and 142 in June 2001. Goodwill amortization will cease upon adoption (effective Jan 1, 2002), replaced by annual impairment testing. In Q2 2001, goodwill amortization reduced EPS by $0.08.
Risks and Contingencies:
- Legal Proceedings: Humana is involved in significant litigation, including the Chipps v. Humana case with an $80 million verdict (mostly punitive damages) currently on appeal. The company is also a defendant in industry-wide class actions regarding RICO and ERISA violations. Management believes insurance may not cover punitive damages in certain jurisdictions.
- Government Contracts: A significant portion of revenue comes from government programs (Medicare+Choice, Medicaid, TRICARE). Legislative changes or contract non-renewals (e.g., Puerto Rico contracts expiring August 2001) pose material risks.
- Regulatory Environment: Increased scrutiny on managed care practices, potential "Patient Bill of Rights" legislation, and HIPAA compliance requirements could increase costs and litigation exposure.
- Prescription Drug Costs: Rising drug costs and the introduction of new, expensive treatments remain a key risk to profitability.
Investor Verification Checklist
- Legal Exposure: Verify the status of the Chipps appeal and the potential for uninsured punitive damages.
- Government Contract Renewals: Monitor the outcome of the Puerto Rico Medicaid contract bidding and potential legislative changes to Medicare reimbursement rates.
- Medical Cost Trends: Assess whether the improved medical expense ratios are sustainable given the exit of non-core markets and potential inflation in remaining markets.
- Debt Structure: Confirm the final terms of the new credit facility and the impact of the recent $300 million senior note issuance on leverage ratios.
- Membership Quality: Evaluate the profitability of the newly acquired TRICARE members versus the declining Commercial membership base.